Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled Trials-Reference-Cited by-同舟云学术

Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled Trials

Published:2016-03 Issue:2 Volume:17 Page:91-94
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Giuliani Jacopo,Bonetti Andrea

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference20 articles.

1. How and when to use genetic markers for nonsmall cell lung cancer;Lazarus;Curr Opin Pulm Med,2013

2. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis;Lee;J Natl Cancer Inst,2013

3. 2nd ESMO consensus conference on lung cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease;Besse;Ann Oncol,2014

4. Cancer's next frontier: addressing high and increasing costs;Elkin;JAMA,2010

5. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis;Cohn;J Clin Oncol,2011

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Entrectinib as first-line vs. second-line therapy in ROS1 fusion-positive non-small cell lung cancer: a cost-effectiveness analysis;Translational Lung Cancer Research;2024-04

2. Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by EGFR mutation type;Journal of Medical Economics;2024-02-13

3. Cost-Effectiveness Analysis of 6 Tyrosine Kinase Inhibitors as First-Line Treatment for ALK-Positive NSCLC in China;Clinical Medicine Insights: Oncology;2024-01

4. Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece;Expert Review of Pharmacoeconomics & Outcomes Research;2023-11-24

5. Knockdown of replication protein A 3 induces protective autophagy and enhances cisplatin sensitivity in lung adenocarcinoma by inhibiting AKT/mTOR signaling via binding to cyclin‐dependent kinases regulatory subunit 2;Drug Development Research;2022-07-28